Inside the Agencies: How regulators are shaping the next era of Pharma Innovation

Regulatory expectations in sterile manufacturing are evolving fast. 

Agencies such as the FDA, MHRA and EMA are sending a clear message to industry: innovation is needed, and they are ready to support it. At ISPE Europe 2026, Alf Penfold, Technical Director – GMP at PM Group, outlined how this regulatory shift is taking shape. He also highlighted what it means for organisations upgrading sterile facilities and processes

A new dynamic: Regulators as innovation partners

Regulators today are increasingly proactive. They want early conversations, not last minute submissions. This helps ensure new ideas are safe, compliant and well designed. As Alf explained, “The agencies want to see meaningful innovation. When you involve them early, the dialogue becomes collaborative instead of corrective.”

This shift represents a major change from traditional regulatory interactions. Early engagement gives manufacturers clearer expectations, fewer surprises and faster decisions. Ultimately, this stands as a major benefit for any long term facility investment. 

Learning through examples  - not just guidance

Regulators respond well when companies share practical, real world examples of technologies that reduce human intervention and contamination risk. These examples help them understand how industry is responding to Annex 1 and where new design strategies are heading. 

These discussions are not about promoting a specific technology. They are about helping agencies understand how risk can be engineered out of a process, not managed day to day. 

A clearer path to Regulatory Confidence

Productive engagement is not about volume - it’s about clarity. Regulators want to see how decisions connect. 

• Strong programmes tend to show: 
• Early alignment between design, operations and quality 
• Annex 1 thinking built into design, not added later 
• Risk tools that shape decisions, not sit untouched 
• A clear contamination control strategy that ties everything together 

This joined up approach helps agencies see the logic behind each choice, which builds trust and confidence in the design. 

What this means for manufacturers now

Across agencies, the direction is consistent. Sterile manufacturing needs to be more controlled and less dependent on human intervention. Digital traceability and clear contamination control logic are becoming basic expectations. Early agency engagement is now one of the most reliable ways to reduce uncertainty and avoid misalignment later. 

Manufacturers that follow this approach are better prepared for Annex 1 reviews. They are more resilient during inspections. They can also be confident their facilities will stay fit for purpose over time. In a fast‑moving regulatory environment, early clarity is no longer a luxury - it is a strategic advantage.

Read more on sterility and future‑ready manufacturing